Our members

Bioaster

Created in 2012, following the French initiative of Technology Research Institutes, BIOASTER
is a non-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology. In particular, BIOASTER uses and develops high value
technological innovations that accelerate development of medical solutions for populations and
personalized medicine. The aim of BIOASTER is to bring together academic, industry and its
capacities and specific knowledge to develop and execute high impact collaborative projects
requiring industry compatible innovative technologies.

www.bioaster.org

Biocodex 

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Orphan diseases; Women’s health. With 1,600 employees, Biocodex generated net revenues of €418 million in 2021, including 42% in France and 58% internationally. The group is present in 124 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.

www.biocodex.com/en

Biofortis

Biofortis is a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science for Human and Animal Health

https://www.biofortis.fr/home/

BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via its own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. 

biogaiagroup.com

Biose Industrie

Biose Industrie has a world leading position as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), specialized in Live Biotherapeutic Products.
Founded in 1951, the company has over 70 years’ experience in the development and production of live bacteria-based drugs.
Biose industrie is a one-stop-CDMO and has three technical platforms:

1. Process Development and optimization for DS & DP,
2. DS GMP production up to 5 000L bioreactors,
3. DP GMP production including capsules, tablets, sachets, oil & cream formulations and Bulk powder.

www.biose.com

Eligo bioscience

Eligo Bioscience is the world leader in microbiome gene editing therapy and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in inflammation, autoimmunity and oncology caused by the expression of specific deleterious bacterial genes by our microbiome. Eligo’s lead program, EB003, is aimed at the targeted eradication of a gut pathogen for a significant unmet medical need. First in human studies are planned in 2022.

Eligo was founded by scientists from The Rockefeller University, where CRISPR-based antimicrobials were invented, and by scientists from MIT. Eligo was named a Technology Pioneer by the World Economic Forum in 2017. With venture capital funding from Khosla Ventures and Seventure Partners, and non-dilutive funding from GlaxoSmithKline, the European Commission, CARB-X, and Bpifrance, Eligo has built an extensive pipeline of drug candidates using its Eligobiotics® platform.

eligo.bio

The Enosis Santé association was created in 2022 by 4 French healthcare clusters: BioValley France, Eurobiomed, Lyonbiopole Auvergne-Rhône-Alpes and Medicen Paris Region.

Through increased inter-cluster synergies, Enosis Santé aims to boost each cluster’s capacity to accelerate the development of healthtech innovation, support innovative companies and reinforce France’s leadership in healthcare.

www.enosis-sante.fr

EnteroBiotix

EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics for patients with serious unmet medical needs. The Company is leveraging its product platform to address patient needs through a pipeline of tailored high-diversity products that fortify and restore the microbiome.

www.enterobiotix.com/

GMT

GMT Science has pioneered the development of innovative medical tests leveraging gut microbiome analysis to improve the clinical management of chronic diseases. The Company provides medical laboratories worldwide with a metagenomics platform enabling clinical assessment of the gut microbiome.

gmt.bio

Created on January 1, 2020, the French National Research Institute for Agriculture, Food, and Environment (INRAE) is a major player in research and innovation. INRAE carries out targeted research and resulted from the merger of INRA and IRSTEA. It is a community of 12,000 people with 273 research, experimental research, and support units located in 18 regional centres throughout France. Internationally, INRAE is among the top research organisations in the agricultural and food sciences, plant and animal sciences, as well as in ecology and environmental science. It is the world’s leading research organisation specialising in agriculture, food and the environment. INRAE’s goal is to be a key player in the transitions necessary to address major global challenges. Faced with a growing world population, climate change, resource scarcity, and declining biodiversity, the institute is developing solutions that involve multiperformance agriculture, high-quality food, and the sustainable management of resources and ecosystems.

MetaGenoPolis (INRAE) deploys a unique set of high-speed platforms for functional & quantitative metagenomics in order to understand the links between food-microbiota-health.

www.inrae.fr/en

Lallemand Health Solutions

World leader in fermentation, Lallemand is a private Canadian company, founded at the end of the 19th century. The company has 11 business units which develop, produce and market products based on yeasts, bacteria and their derivatives for the food, human and animal health markets, and for agricultural applications, reaching hundreds of thousands of consumers every day. Lallemand operates 48 sites on 5 continents.

www.lallemand.com

Life Avocats is a law firm which assists organisations involved in digital health and life sciences with all the regulatory issues relating to the life cycle of their products and solutions: development, pre-clinical and clinical research, market access, distribution, health inspections.

www.life-avocats.com/

MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.
The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

maatpharma.com

mbiomics

mbiomics designs and develops complex microbiome-based therapeutics to change the treatment
paradigm of severe and chronic diseases. Bringing together proprietary precision analytics and patient
insights, we are building a pipeline of rationally selected microbial communities to achieve indicationspecific activity and address patient heterogeneity. Our goal is to access the gut microbiome's full
immunological and metabolic potential to restore healthy microbial ecosystems and thereby
overcome disease.

mbiomics.com

Microbiome Foundation

The Microbiome Foundation's aim is to promote a new paradigm in healthcare, towards a more personalized
and preventative approach that maintains each individual’s “health capital”. The Microbiome Foundation is a French non-profit organization whose aim is to raise funds, from corporates and private donors, to work towards the following goals: funding cutting-edge research on the gut microbiota, in connection with chronic diseases (obesity, diabetes, autism, Parkinson’s, Alzheimer’s, NASH etc.), whose incidence is highly correlated with poor nutrition ; and raising public awareness about the critical role of nutrition in shaping the microbiota and preserving one’s “health capital”.

www.microbiome-foundation.org

Microbiotica

Microbiotica is a private, clinic-ready, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. The company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.

microbiotica.com

MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and
metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical
development in Ulcerative Colitis and/or in the orphan disease indication Pouchitis. MRM Health
leverages its proprietary disruptive CORAL® technology platform to design microbiome-based
biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to
optimize them for faster onset-of-action and increased potency and robustness. A significant
differentiator is the ability to manufacture these consortia as single drug substance in a single
standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory
Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and
Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.

mrmhealth.com

Nexbiome Therapeutics

Nexbiome Therapeutics is a private incubator, funding and operating projects in microbiome-based human therapeutic solutions, from early-stage to spin-off.

www.nexbiome.com

Novobiome

NovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-inclass therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and NonAlcoholic Steato-Hepatitis (NASH). The Company is developing an ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates.
NovoBiome is headquartered in France.

www.novobiome.eu

Pelican Health specializes in precision medicine and offers solutions for studying the intestinal microbiome for diagnostic purposes. However, accessing this microbial information currently relies on complex, invasive, expensive, or unrepresentative methods. This is where Pelican Health comes in with a non-invasive, user-friendly, accurate, cost-effective, and scalable solution. This solution comes in the form of a Class IIa device the size of an ingestible pharmaceutical capsule, without electronics, and capable of multiple sample collections.

www.pelican-health.com

Seventure Partners

With €850m net commitments under management as of the end of 2020, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe and North America. In Digital technologies, the three main areas of focus include Fintech / Insurtech, innovative services and software. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Investment Managers. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second largest French bank.

www.seventure.fr/en

SwipeBiome is a French corporation leading tech-bio innovation, shaping the future of the biotics industry through microbiome breakthroughs and personalised solutions.

swipebiome.com